GlassScriptPhysician profile
Maria Rocio Reyes
NPI 1235254640
$5,405.08
in general payments reported to CMS, 2019-2025
28 companies · $1,046 in 2025
The $1,046 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $582 · 2021: $446 · 2022: $531 · 2023: $780 · 2024: $896 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498 · Education: $177 · Consulting Fee: $45.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.73 |
| Education | $177.49 |
| Consulting Fee | $45.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $850.34 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $832.46 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $778.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $513.90 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $258.89 | 2019-2024 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $258.67 | 2019-2025 | |
| Pharming Healthcare, INC. | $250.21 | 2019-2024 | Ruconest |
| Optinose US, INC. | $206.84 | 2019-2025 | |
| Amgen INC. | $142.09 | 2022-2025 | Tezspire |
| Genzyme Corporation | $142.03 | 2020-2025 | |
| Abbvie INC. | $139.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $138.98 | 2019-2020 | |
| Kaleo, INC. | $109.27 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $108.59 | 2022 | |
| Pfizer INC. | $97.29 | 2019-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $95.68 | 2019 | |
| Blueprint Medicines Corporation | $78.87 | 2023-2024 | Ayvakit |
| Genentech USA, INC. | $78.44 | 2019-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $69.99 | 2025 | |
| Bio Products Laboratory USA, INC. | $51.22 | 2019-2023 | Coagadex, Gammaplex |
| Adma Biomanufacturing LLC | $45.99 | 2024 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.20 | 2019 | |
| Hospira, INC. | $24.38 | 2019 | |
| Alk-Abello, INC | $22.92 | 2019 | |
| Hikma Pharmaceuticals USA | $19.67 | 2024 | Ryaltris |
| Octapharma USA, INC. | $18.58 | 2021 | |
| Merck Sharp & Dohme LLC | $17.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.